Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/7/2025 | $20.00 | Outperform | Leerink Partners |
| 4/8/2025 | Outperform | William Blair |
PALO ALTO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate at an upcoming Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum. Details: Type: Fireside ChatSpeakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical OfficerDate: Tuesday, May 27th, 2025Time: 08:00 am ETLocation: Webcast Following the event, a replay will be hosted on Kalaris Therapeutics' Investor Relations webpage. About Kalaris Kalaris is a clinical-stage
SCHEDULE 13G/A - Kalaris Therapeutics, Inc. (0001754068) (Subject)
10-Q - Kalaris Therapeutics, Inc. (0001754068) (Filer)
8-K - Kalaris Therapeutics, Inc. (0001754068) (Filer)
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
4 - Kalaris Therapeutics, Inc. (0001754068) (Issuer)
Leerink Partners initiated coverage of Kalaris Therapeutics with a rating of Outperform and set a new price target of $20.00
William Blair initiated coverage of Kalaris Therapeutics with a rating of Outperform